Clinton, Joseph William http://orcid.org/0000-0002-9040-4302
Kiparizoska, Sara
Aggarwal, Soorya
Woo, Stephanie
Davis, William
Lewis, James H.
Article History
Accepted: 5 August 2021
First Online: 17 September 2021
Declarations
:
: No sources of funding were used to assist in the preparation of this article.
: Joseph Clinton, Sara Kiparizoska, Soorya Aggarwal, Stephanie Woo, and William Davis have no conflicts of interest that are directly relevant to the content of this article. James H. Lewis has consulting agreements or serves on drug safety monitoring boards for Allergan, Akebia, Alexion, Athira, Boehringer Ingelheim, Cleveland Clinic, Daiichi Sankyo, F2G, Galectin, Innate, Intercept, Lipocine, Madrigal, Novartis, Orphazyme, Palladio, Pfizer, Reata, Sanofi, TPG, Tsumura, Vertex, Zydus, and BMS, but otherwise has no other conflicts of interest.
: There was no need for ethical approval.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: All authors contributed to the study conception and design and to revising it critically for content. All authors read and approved the final version.
Free to read: This content has been made available to all.